Perception of pathogen (or microbe)-associated molecular patterns (PAMPs/MAMPs) by pattern recognition receptors (PRRs) is a key component of plant innate immunity. The Arabidopsis PRR EF-Tu receptor (EFR) recognizes the bacterial PAMP elongation factor Tu (EF-Tu) and its derived peptide elf18. Previous work revealed that transgenic expression of AtEFR in Solanaceae confers elf18 responsiveness and broad-spectrum bacterial disease resistance. In this study, we developed a set of bioassays to study the activation of PAMP-triggered immunity (PTI) in wheat. We generated transgenic wheat (Triticum aestivum) plants expressing AtEFR driven by the constitutive rice actin promoter and tested their response to elf18. We show that transgenic expression of AtEFR in wheat confers recognition of elf18, as measured by the induction of immune marker genes and callose deposition. When challenged with the cereal bacterial pathogen Pseudomonas syringae pv. oryzae, transgenic EFR wheat lines had reduced lesion size and bacterial multiplication. These results demonstrate that AtEFR can be transferred successfully from dicot to monocot species, further revealing that immune signalling pathways are conserved across these distant phyla. As novel PRRs are identified, their transfer between plant families represents a useful strategy for enhancing resistance to pathogens in crops.

Download full-text PDF

Source
http://dx.doi.org/10.1111/nph.13356DOI Listing

Publication Analysis

Top Keywords

ef-tu receptor
8
bacterial disease
8
disease resistance
8
transgenic wheat
8
transgenic expression
8
expression atefr
8
bacterial
5
transgenic
5
wheat
5
arabidopsis ef-tu
4

Similar Publications

Article Synopsis
  • Vector-borne bacterial pathogens negatively impact crops globally, resulting in significant financial losses due to their host- and vector-dependent evolution that has led to a reduced genome size.
  • Research focused on three specific protein features from these pathogens revealed that they have fewer genes related to flagellin and cold shock proteins compared to their free-living relatives, making them less effective at provoking immune responses in plants.
  • The study also found that certain epitopes from the 'Candidatus Liberibacter asiaticus' can trigger immune responses in some plants, indicating that these pathogens have adapted mechanisms to evade detection by their hosts.
View Article and Find Full Text PDF
Article Synopsis
  • Plants use pattern recognition receptors (PRRs) like EFR and FLS2 to detect bacterial pathogens and activate their immune response via RBOHD.
  • QSK1, identified as a protein associated with the PRR-RBOHD complex, acts as a negative regulator by downregulating EFR and FLS2, leading to suppressed immunity.
  • The bacterial effector HopF2Pto manipulates QSK1 to inhibit immune responses, demonstrating the sophisticated interplay between plant defense mechanisms and pathogen strategies.
View Article and Find Full Text PDF
Article Synopsis
  • The case study discusses a female patient diagnosed with achondroplasia due to an FGFR3 gene variant, but her symptoms indicated a more complex condition, prompting further genetic analysis.* -
  • Despite her initial diagnosis, the patient exhibited unusual features such as small head size, distinct facial characteristics, speech delay, and hearing loss, leading to her participation in extensive genetic research efforts.* -
  • Ultimately, the discovery of an EFTUD2 gene rearrangement revealed a second diagnosis of mandibulofacial dysostosis with microcephaly, marking a rare instance of dual genetic disorders in one individual and emphasizing the need for careful genetic evaluations.*
View Article and Find Full Text PDF

Severe fever with thrombocytopenia syndrome is an emerging viral hemorrhagic fever caused by a tick-borne bunyavirus, severe fever with thrombocytopenia syndrome virus (SFTSV), with a high case fatality. We previously found that SFTSV nucleoprotein (NP) induces macroautophagy/autophagy to facilitate virus replication. However, the role of NP in antagonizing host innate immunity remains unclear.

View Article and Find Full Text PDF

Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, was approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) based on the results from pivotal Cohorts 1+2 of ZUMA-1 (NCT02348216). ZUMA-1 was expanded to investigate safety management strategies aimed at reducing the incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs). Prospective safety expansion Cohort 5 evaluated the impact of debulking therapy, including rituximab-containing immunochemotherapy regimens and radiotherapy, in axi-cel-treated patients; the CRS and NE management strategy paralleled those in Cohorts 1+2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!